US FDA finds no clear link of heart attacks and GSK's abacavir drugs
This article was originally published in Scrip
Executive Summary
After an investigation lasting nearly three-years, the US FDA concluded that there is not an increased risk of heart attacks associated with abacavir, the active ingredient in GlaxoSmithKline's HIV drug Ziagen, a nucleoside analogue. Abacavir also is one component in GSK's combination HIV drugs Trizivir (abacavir sulfate, lamivudine, and zidovudine) and Epzicom abacavir sulfate and lamivudine).